Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05019976 · ClinicalTrials.gov registry record · NA
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
A NA study of Lymphoma and Non-Hodgkin Lymphoma, sponsored by University of Chicago.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05019976: Active NA study of Lymphoma and Non-Hodgkin Lymphoma, sponsored by University of Chicago.
NCT05019976 is a NA study of Lymphoma and Non-Hodgkin Lymphoma that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 30 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05019976, a NA study of Lymphoma and Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study focuses on using shortened courses of radiation for participants with relapsed/refractory Hodgkin/Non-Hodgkin lymphoma. Treatment radiation over 5-6 weeks is often standard of care for many people with lymphoma, but doctors leading this study aim to find out if using radiation for a shorter period of time can be safe for treating lymphoma and if so, what is the safest shortened dose of radiation for participants.
Primary Outcome
Maximum tolerated dose of radiation per fraction among participants with relapsed/refractory Hodgkin/non-Hodgkin lymphoma as assessed by dose-limiting toxicities (severe side effects that limit the dose of radiation) defined by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Conditions Studied
Interventions
- RADIATION Radiation - Dose Level 0
- RADIATION Radiation - Dose Level 1
- RADIATION Radiation - Dose Level 2
- RADIATION Radiation - Dose Level 3
- RADIATION Radiation - Dose Level 4
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2027-12-01 |
| Phase | NA |
What the registry record for NCT05019976 still lists
NCT05019976 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Radiation - Dose Level 0 is the first listed.
NCT05019976 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05019976 about?
NCT05019976 is a clinical study titled "Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma". This study focuses on using shortened courses of radiation for participants with relapsed/refractory Hodgkin/Non-Hodgkin lymphoma. Treatment radiation over 5-6 weeks is often standard of care for many people with lymphoma, but doctors leading this study aim to find out if using radiation for a short...
What is the current status of trial NCT05019976?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2021-09-30. Estimated completion is 2027-12-01.
What conditions does trial NCT05019976 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma.
What interventions are being tested in trial NCT05019976?
The interventions under investigation include: Radiation - Dose Level 0 (RADIATION), Radiation - Dose Level 1 (RADIATION), Radiation - Dose Level 2 (RADIATION), Radiation - Dose Level 3 (RADIATION), Radiation - Dose Level 4 (RADIATION).
Who is sponsoring clinical trial NCT05019976?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05019976 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05019976's enrollment target sits among peer trials
30 214th of 299 higher than 76 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI